Response to 'Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence' by Smith et al. [5]

AIDS

Volumn 18, Issue 18, 2004, Pages 2448-

  Bhaduri, Sumit ^a   Miller, Alastair R O ^a  

^a S Worcestershire Primary Care Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; DIDANOSINE; LOPINAVIR PLUS RITONAVIR;

DRUG SUBSTITUTION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; LETTER; LYMPHOCYTE COUNT; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD; VIRUS MUTATION; WILD TYPE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; HIV INFECTIONS; HUMANS;

EID: 11244355917     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. Smith DE, Walker BD, Cooper DA, Rosenberg EA, Kaldor JM. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS 2004; 18: 709-716.
2. British HIV Association. Guidelines for the treatment of HIV infected adults with antiretroviral therapy. Available at: www. bhiva.org/guidelines/ 2003/hiv/start/html. Site accessed: 08 June 2004.